Samsung Biologics Secures 97.98% of Polypeptide Group in Tender Offer

Samsung Biologics has secured a 97.98% stake in its tender offer for global peptide contract development and manufacturing organization (CDMO) Polypeptide

By Tom Reyes · Markets Editor

Nov 2 01:26 ETSource: 아시아경제

From the source

Samsung Biologics Secures 97.98% of Polypeptide Group in Tender Offer
Samsung Biologics has secured a 97.98% stake in its tender offer for global peptide contract development and manufacturing organization (CDMO) Polypeptide Group.

Read at asiae.co.kr

Source URL https://www.asiae.co.kr/en/article/2026110215260496526